Start from a saved view, or filter by area, exchange and headquarters. Each row shows the pipeline, its most advanced asset and the next readout on record.
Lists by late-stage drug kind: biologics, small molecules, cell and gene therapies, RNA and oligonucleotide drugs, peptide drugs.
1457 of 1457 companies
| Company | Pipeline | Most advanced | Next readout | Market cap | Cash & inv. | Runway | R&D / yr |
|---|---|---|---|---|---|---|---|
Luye Pharma Group2186 · HKEX | 12 assets: 4 approved, 4 Ph 3, 2 Ph 2, 2 Ph 1 | Ansofaxine hydrochloridePhase 3 · Major Depressive DisorderReliable signal | 28 Feb 2027Ansofaxine hydrochloride · Approved | — | — | — | $260M |
Mabwell Bioscience688062 · SSE STAR Market | 3 assets: 2 Ph 3, 1 Ph 2 | 7MW3711Phase 3 · Non-Small Cell Lung Cancer | Dec 20279MW1911 · Phase 2 | — | — | — | ~$95M |
Mayne PharmaMYX · ASX | 2 assets: 2 approved | Approved assets only | None on record | — | — | — | — |
Medicenna Therapeutics, Inc.MDNA · TSX | 2 assets: 2 Ph 2 | bizaxofuspPhase 2 · Recurrent Glioblastoma | 20 Oct 2028MDNA11 · Phase 1/2 | — | — | — | — |
MedincellMEDCL · Euronext Paris | 2 assets: 2 approved | Approved assets only | None on record | — | — | — | — |
Medivir ABMVIR · Nasdaq Stockholm | 1 asset: 1 Ph 2 | BirinapantPhase 2 · Ovarian Cancer | None on record | — | — | — | — |
MeiraGTx LimitedMGTX · Nasdaq | 1 asset: 1 Ph 2 | AAV-GAD gene therapyPhase 2 · Parkinson's DiseaseWeak signal | Oct 2029AAV-GAD gene therapy · Phase 1/2 | — | $187MSep 2026 | Cash-flow positive | $160M |
MendusIMMU · Nasdaq Stockholm | 1 asset: 1 Ph 2 | VididencelPhase 2 · Acute Myeloid LeukemiaWeak signal | 1 Sep 2029Vididencel · Phase 1 | — | $7.0MDec 2025 | Ended May 2026 | ~-$9.1M |
Merck KGaAMKKGY · OTC | 8 assets: 7 approved, 1 Ph 3 | precemtabart tocentecanPhase 3 · Metastatic Colorectal Cancer | Apr 2027Cetuximab · Phase 1/2 | —no price since 18 Aug 2026 | — | Profitable | — |
Mezzion Pharma140410 · KOSDAQ | 1 asset: 1 Ph 3 | UdenafilPhase 2/3 · Pulmonary Arterial HypertensionWeak signal | None on record | — | — | — | — |
Molecular PartnersMOLN · | 2 assets: 2 Ph 1 | MP0310Phase 1 · Advanced Solid Tumors | None on record | — | $117MDec 2025 | ~7.6 qtrs | $48M |
Nanjing Leads Biolabs Co.,Ltd9887 · HKEX | 3 assets: 2 Ph 2, 1 Ph 1 | OpamtistomigPhase 2 · Non-Small Cell Lung Cancer | Dec 2026Opamtistomig · Phase 1/2 | — | $59MMar 2025 | Ended Sep 2026 | ~$32M |
NanobiotixNBTX · Nasdaq | 1 asset: 1 Ph 3 | NBTXR3Phase 3 · Head and Neck Squamous Cell Carcinoma | 30 Apr 2027NBTXR3 · Phase 1 | — | $62MDec 2025 | ~6.5 qtrs | $26M |
Nature Cell Co., Ltd.007390 · KOSDAQ | 1 asset: 1 Ph 2 | AstroStemPhase 2 · Alzheimer's DiseasePartial signal | None on record | — | — | — | — |
Neuren PharmaceuticalsNEU · ASX | 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — |
Newron Sweden ABPrivate | 1 asset: 1 other | TelberminDiscontinued | None on record | — | — | — | — |
Nippon Kayaku4272 · TSE | 2 assets: 1 approved, 1 Ph 2 | DarinaparsinPhase 2 · Peripheral T-Cell LymphomaWeak signal | 2 Feb 2027Taletrectinib · Phase 1 | — | — | — | — |
Nippon Shinyaku4516 · TSE | 6 assets: 4 approved, 2 Ph 3 | Clemidsogene lanparvovecPhase 3 · Mucopolysaccharidosis Type II | 30 Apr 2027Ferric derisomaltose · Phase 3 | — | — | — | — |
NKGen BiotechNKGN · OTC | 1 asset: 1 Ph 2 | TroculeucelPhase 1/2 · Alzheimer's DiseaseWeak signal | Mar 2028Troculeucel · Phase 1/2 | —no price since 18 Aug 2026 | <$0.1MMar 2025 | Ended Mar 2025 | $9.3M |
Nova Pneuma Inc.Private | 1 asset: 1 Ph 3 | Staccato AlprazolamPhase 3 · EpilepsyReliable signal | 29 Mar 2027Staccato Alprazolam · Phase 3 | — | — | — | — |
Nxera Pharma4565 · TSE | 1 asset: 1 Ph 3 | DireclidinePhase 3 · SchizophreniaPartial signal | Oct 2027Direclidine · Phase 3 | — | — | — | — |
Obsidian Therapeutics, Inc.OBX · Nasdaq | 1 asset: 1 Ph 2 | OBX-115Phase 1/2 · Non-Small Cell Lung Cancer | 30 Jun 2029OBX-115 · Phase 1/2 | — | $216MSep 2026 | ~11.2 qtrs | $89M |
Oneness Biotech4743 · TPEx | 1 asset: 1 Ph 2 | FB825Phase 2 · Atopic DermatitisWeak signal | 31 May 2027FB825 · Phase 2 | — | — | — | — |
Ono Pharmaceutical4528 · TSE | 16 assets: 11 approved, 1 Ph 3, 2 Ph 2, 2 Ph 1 | ONO-4578Phase 3 · Gastric CancerReliable signal | 10 Dec 2026Dapagliflozin · Phase 2 | — | $1.5BMar 2026 | — | $969M |
OrganonOGN · NYSE | 12 assets: 11 approved, 1 other | Atozet (ezetimibe/atorvastatin)Atherosclerotic Cardiovascular Disease | Aug 2027Tapinarof · Phase 3 | — | $1.5BSep 2026 | Cash-flow positive | $357M |
Orient EuroPharma4120 · TPEx | 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — |
Orion CorporationORNBV · Nasdaq Helsinki | 2 assets: 1 approved, 1 Ph 3 | LevosimendanPhase 3 · Heart FailurePartial signal | 30 Jun 2028Levosimendan · Phase 3 | — | $189MDec 2025 | — | $239M |
Oryzon Genomics, S.A.ORY · BME | 1 asset: 1 Ph 2 | IadademstatPhase 2 · Acute Myeloid LeukemiaWeak signal | None on record | — | $33MDec 2025 | ~8.3 qtrs | $14M |
Oscotec Inc.039200 · KOSDAQ | 1 asset: 1 Ph 1 | OCT-598Phase 1 · Non-Small Cell Lung Cancer | Dec 2027OCT-598 · Phase 1 | — | — | — | — |
OSE ImmunotherapeuticsOSE · Euronext Paris | 2 assets: 1 Ph 3, 1 Ph 2 | OSE2101Phase 3 · Non-Small Cell Lung CancerPartial signal | 1 May 2028OSE2101 · Phase 3 | — | — | — | — |
Otsuka Holdings4578 · TSE | 23 assets: 15 approved, 4 Ph 3, 2 Ph 2, 2 Ph 1 | UlefnersenPhase 3 · Amyotrophic Lateral SclerosisReliable signal | Dec 2026Donidalorsen · Phase 3 | — | $3.4BMar 2026 | — | ~$2.1B |
Parataxis Korea, Inc.288330 · KOSDAQ | 1 asset: 1 Ph 2 | BBT-207Phase 1/2 · Non-Small Cell Lung Cancer | None on record | — | — | — | — |
PegBio2565 · HKEX | 3 assets: 2 Ph 3, 1 Ph 2 | Visepegenatide (PB-119)Phase 3 · Type 2 DiabetesReliable signal | None on record | — | — | — | — |
Peptron087010 · KOSDAQ | 1 asset: 1 Ph 2 | Exenatide (PT320)Phase 2 · Parkinson's DiseasePartial signal | None on record | — | — | — | — |
PharmaEngine4162 · TPEx | 1 asset: 1 Ph 1 | PEP07Phase 1 · Acute Myeloid Leukemia | 31 Dec 2026PEP07 · Phase 1 | — | — | — | — |
PharmaEssentia Corporation6446 · TWSE | 1 asset: 1 approved | Approved assets only | 18 Nov 2027Ropeginterferon alfa-2b (Besremi) · Phase 3 | — | — | — | — |
PharmaMarPHM · BME | 2 assets: 1 approved, 1 Ph 3 | PlitidepsinPhase 3 · Multiple MyelomaPartial signal | 31 Dec 2027Lurbinectedin · Phase 3 | — | — | — | — |
Pharmosa Biopharm Inc.6875 · TPEx | 1 asset: 1 Ph 3 | Treprostinil (L606)Phase 3 · Pulmonary Arterial Hypertension | Jul 2029Treprostinil (L606) · Phase 3 | — | — | — | — |
Pila PharmaPILA · Nasdaq First North | 1 asset: 1 Ph 2 | XEN-D0501Phase 2 · Type 2 DiabetesPartial signal | None on record | — | $1.7MDec 2025 | Ended Apr 2026 | — |
Polaris Group6550 · TWSE | 1 asset: 1 Ph 3 | PegargiminasePhase 3 · Hepatocellular CarcinomaWeak signal | Jan 2027Pegargiminase · Phase 1 | — | — | — | — |
Prestige Biopharma Limited950210 · KOSPI | 1 asset: 1 Ph 3 | HD204Phase 3 · Non-Small Cell Lung CancerReliable signal | None on record | — | — | — | — |
ProGen296160 · KONEX | 2 assets: 1 Ph 2, 1 Ph 1 | PG-102Phase 2 · ObesityPartial signal | 1 Dec 2026RT-114 · Phase 1 | — | — | — | — |
| 1 asset: 1 other | LinebackerSolid Tumors | None on record | —no price since 18 Aug 2026 | <$0.1MJun 2026 | Ended Jul 2026 | $0.1M | |
Prothena Biosciences LimitedPRTA · Nasdaq | 2 assets: 1 Ph 3, 1 Ph 2 | PrasinezumabPhase 3 · Parkinson's Disease | 17 Dec 2026Moponetug · Phase 2 | — | $272MSep 2026 | ~9.6 qtrs | $83M |
Provectus PharmaceuticalsPVCT · OTC | 2 assets: 1 Ph 3, 1 Ph 2 | rose bengal disodiumPhase 3 · Locally Advanced Cutaneous Melanoma | None on record | —no price since 18 Aug 2026 | — | ~1.9 qtrsJun 2026 | $1.0M |
PureTech HealthPTCHF · OTC | 2 assets: 2 Ph 2 | GlyphAllo (allopregnanolone prodrug)Phase 2 · Major Depressive Disorder | Mar 2027GlyphAllo (allopregnanolone prodrug) · Phase 2 | —no price since 18 Aug 2026 | $281MDec 2024 | ~8.4 qtrs | $69M |
Quince TherapeuticsQNCX · Nasdaq | 1 asset: 1 Ph 2 | LAM-001Phase 2 · Pulmonary Hypertension Associated with Interstitial Lung Disease | None on record | —no price since 9 Oct 2026 | $105MSep 2026 | ~8.6 qtrs | $31M |
Qyuns Therapeutics2509 · HKEX | 1 asset: 1 Ph 3 | HS-20137Phase 3 · Psoriasis | 1 Mar 2027HS-20137 · Phase 2 | — | — | — | — |
Radiopharm Theranostics, LtdRADX · Nasdaq | 4 assets: 2 Ph 2, 2 Ph 1 | RAD101Phase 2 · Brain Metastases | Dec 2027RAD202 · Phase 1 | — | $29MJun 2025 | Ended May 2026with a later raise | $28M |
RecordatiREC · Euronext Milan | 4 assets: 3 approved, 1 other | LercanidipineHypertension | None on record | — | — | — | — |
REGENXBIO Inc.RGNX · Nasdaq | 3 assets: 3 Ph 3 | Surabgene lomparvovecPhase 3 · Age-Related Macular DegenerationWeak signal | Dec 2026Surabgene lomparvovec · Phase 2/3 | — | $251MSep 2026 | ~6.6 qtrs | $234M |
RemeGen Co., Ltd.688331 · SSE | 6 assets: 4 Ph 3, 1 Ph 2, 1 Ph 1 | TelitaciceptPhase 3 · Rheumatoid ArthritisReliable signal | Dec 2026Disitamab Vedotin · Phase 2/3 | — | $213MDec 2025 | — | $170M |
RocheRHHBY · OTC | 68 assets: 23 approved, 20 Ph 3, 7 Ph 2, 4 Ph 1, 14 other | astegolimabPhase 3 · Chronic Obstructive Pulmonary DiseaseReliable signal | Nov 2026Venetoclax · Phase 2 | —no price since 18 Aug 2026 | — | — | $14.7B |
Rohto Pharmaceutical4527 · TSE | 1 asset: 1 Ph 2 | ADR-002KPhase 2 · Heart Failure | 30 Sep 2028ADR-002K · Phase 2 | — | $522MMar 2026 | — | $91M |
Roivant Sciences Ltd.ROIV · Nasdaq | 3 assets: 1 approved, 2 Ph 3 | ImeroprubartPhase 3 · Myasthenia Gravis | Dec 2026Mosliciguat · Phase 2 | — | $4.2BSep 2026 | 10+ years | ~$678M |
Ryvu Therapeutics SARVU · GPW | 1 asset: 1 Ph 2 | RomaciclibPhase 2 · Acute Myeloid LeukemiaWeak signal | Dec 2026Romaciclib · Phase 2 | — | $17MDec 2025 | Ended Mar 2026 | $48M |
S.Biomedics304360 · KOSDAQ | 2 assets: 2 Ph 2 | Adipose-derived MSC clusters (S.Biomedics)Phase 1/2 · Atherosclerotic Cardiovascular DiseaseWeak signal | 7 Feb 2029TED-A9 (A9-DPC) · Phase na | — | — | — | — |
Sagimet Biosciences Inc.SGMT · Nasdaq | 1 asset: 1 Ph 3 | DenifanstatPhase 3 · Recurrent GlioblastomaReliable signal | Aug 2027Denifanstat · Phase 3 | — | $236MSep 2026 | ~31.5 qtrswith a later raise | $42M |
Sam Chun Dang Pharm. Co., Ltd.000250 · KOSDAQ | 1 asset: 1 other | Aflibercept (Vgenfli)Age-Related Macular Degeneration | None on record | — | — | — | — |
Sandoz Group AGSDZ · SIX | 9 assets: 9 approved | Approved assets only | None on record | — | — | — | — |
Sangamo TherapeuticsSGMOQ · OTC | 1 asset: 1 Ph 2 | TX200Phase 1/2 · Kidney Transplant Rejection Prophylaxis | None on record | —no price since 18 Aug 2026 | $28MMar 2026 | Ended Jul 2026 | $113M |
SanionaSANION · Nasdaq Stockholm | 1 asset: 1 Ph 3 | TesofensinePhase 3 · ObesityReliable signal | None on record | — | $63MDec 2025 | ~12.8 qtrs | — |
Santen Pharmaceutical Co., Ltd.4536 · TSE | 1 asset: 1 Ph 3 | RC28-EPhase 3 · Age-Related Macular DegenerationPartial signal | 1 Dec 2028RC28-E · Phase 3 | — | — | — | — |
Scilex PharmaceuticalsPrivate | 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — |
SCM Lifescience298060 · KOSDAQ | 1 asset: 1 Ph 2 | SCM-AGHPhase 1/2 · Atopic DermatitisPartial signal | None on record | — | — | — | — |
Shaanxi Micot Pharmaceutical Technology2335 · HKEX | 1 asset: 1 Ph 3 | MT1013Phase 3 · Chronic Kidney DiseasePartial signal | 26 Nov 2026MT1013 · Phase 3 | — | — | — | ~$11M |
Shandong Boan Biotechnology Co., Ltd6955 · HKEX | 1 asset: 1 Ph 1 | BA1302Phase 1 · Non-Small Cell Lung Cancer | 31 Dec 2027BA1302 · Phase 1 | — | — | — | $11M |
Shanghai Bao Pharmaceuticals Co., Ltd.2659 · HKEX | 1 asset: 1 Ph 1 | KJ015Phase 1 · Non-Small Cell Lung Cancer | 31 Dec 2026KJ015 · Phase 1 | — | — | — | — |
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.600196 · SSE | 2 assets: 2 Ph 3 | AR1001Phase 3 · Alzheimer's DiseasePartial signal | 12 May 2027Velinotamig (GR1803) · Phase 2 | — | — | — | — |
| 10 assets: 2 approved, 3 Ph 3, 3 Ph 2, 2 Ph 1 | SerplulimabPhase 3 · Non-Small Cell Lung CancerReliable signal | 1 Dec 2026FCN-338 · Phase 2 | — | — | — | — | |
Shanghai Henlius Biotech2696 · HKEX | 14 assets: 8 Ph 3, 4 Ph 2, 2 Ph 1 | HLX01Phase 3 · Rheumatoid ArthritisReliable signal | 22 Nov 2026HLX43 · Phase 2 | — | — | — | $347M |
Shanghai Junshi Bioscience1877 · HKEX | 8 assets: 1 approved, 4 Ph 3, 2 Ph 2, 1 Ph 1 | OngericimabPhase 3 · Atherosclerotic Cardiovascular DiseaseReliable signal | 27 Nov 2026JS207 · Phase 2 | — | $456MDec 2025 | ~3.7 qtrs | $193M |
Shanghai Pharmaceuticals Holding2607 · SSE | 2 assets: 1 Ph 3, 1 Ph 2 | SPH4336Phase 2/3 · HR+/HER2- Metastatic Breast Cancer | 1 Dec 2026SPH4336 · Phase 2/3 | — | $4.8BDec 2025 | — | $345M |
Shaperon378800 · KOSDAQ | 1 asset: 1 Ph 2 | HY209gelPhase 2 · Atopic DermatitisPartial signal | None on record | — | — | — | — |
Shenzhen Salubris Pharmaceuticals002294 · SZSE | 7 assets: 3 Ph 3, 4 Ph 2 | EnarodustatPhase 3 · Chronic Kidney DiseaseReliable signal | 12 Dec 2026SAL0137 · Phase 2 | — | $157MMar 2026 | — | $79M |
Shijiazhuang Yiling Pharmaceutical Co. Ltd002603 · SZSE | 1 asset: 1 Ph 3 | XY0206Phase 3 · Acute Myeloid Leukemia | 1 Jul 2027XY0206 · Phase 3 | — | — | — | — |
Shin Nippon Biomedical Laboratories2395 · TSE | 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — |
Shionogi4507 · TSE | 7 assets: 5 approved, 2 Ph 3 | EnarodustatPhase 3 · Chronic Kidney DiseaseReliable signal | 25 Jan 2027Rosuvastatin · Phase 1 | — | $4.5BMar 2026 | — | $810M |
Sichuan Baili Pharmaceutical688506 · SSE STAR Market | 9 assets: 3 Ph 3, 4 Ph 2, 2 Ph 1 | IzalontamabPhase 3 · Non-Small Cell Lung Cancer | Nov 2026Izalontamab brengitecan · Phase 3 | — | $430MMar 2026 | — | $350M |
Sichuan Huiyu Pharmaceutical Co., Ltd688553 · SSE STAR Market | 1 asset: 1 Ph 2 | HYP-6589Phase 1/2 · Non-Small Cell Lung Cancer | 10 Apr 2028HYP-6589 · Phase 1/2 | — | — | — | — |
Sichuan Kelun Pharmaceutical Co., Ltd.002422 · SZSE | 1 asset: 1 Ph 1 | Brexpiprazole long-acting injection (Kelun)Phase 1 · Schizophrenia | None on record | — | — | — | — |
| 7 assets: 3 Ph 3, 3 Ph 2, 1 Ph 1 | Sacituzumab TirumotecanPhase 3 · Non-Small Cell Lung CancerPartial signal | Nov 2026Sacituzumab Tirumotecan · Phase 3 | — | $651MDec 2025 | ~12.2 qtrs | $184M | |
Sihuan Pharmaceutical Holdings0460 · HKEX | 1 asset: 1 Ph 3 | janagliflozinPhase 3 · Type 2 DiabetesReliable signal | 31 Dec 2027janagliflozin · Approved | — | $509MDec 2025 | — | $41M |
SillaJen, Inc.215600 · KOSDAQ | 1 asset: 1 Ph 1 | BAL0891Phase 1 · Acute Myeloid Leukemia | 24 Dec 2026BAL0891 · Phase 1 | — | $3.7MDec 2025 | — | $11M |
Simcere Pharmaceutical2096 · HKEX | 9 assets: 7 Ph 3, 2 Ph 1 | ZemprocitinibPhase 3 · Atopic DermatitisReliable signal | Nov 2026Zemprocitinib · Phase 3 | — | — | Profitable | — |
Sino Biopharmaceutical1177 · HKEX | 16 assets: 1 approved, 7 Ph 3, 4 Ph 2, 4 Ph 1 | CulmerciclibPhase 3 · HR+/HER2- Metastatic Breast CancerPartial signal | Dec 2026Culmerciclib · Phase 3 | — | $1.8BDec 2025 | — | $866M |
Sinocelltech Group Ltd.688520 · SSE | 3 assets: 3 Ph 3 | SCTB14Phase 3 · Non-Small Cell Lung Cancer | Apr 2027SCTC21C · Phase 1/2 | — | — | — | $118M |
SinoMab BioScience3681 · HKEX | 1 asset: 1 Ph 2 | SM17Phase 2 · Atopic DermatitisWeak signal | 25 Apr 2027SM17 · Phase 2 | — | — | — | — |
SK Biopharmaceuticals Co., Ltd.326030 · KOSPI | 3 assets: 2 approved, 1 Ph 3 | CarisbamatePhase 3 · EpilepsyPartial signal | Dec 2026Solriamfetol · Phase 3 | — | — | — | — |
SK Chemicals285130 · KOSPI | 1 asset: 1 other | cilostazol/Ginkgo bilobaAtherosclerotic Cardiovascular Disease | None on record | — | $393MDec 2025 | — | — |
SNLD, Ltd.Private | 2 assets: 1 Ph 2, 1 Ph 1 | TR-012001Phase 2 · Parkinson's DiseaseWeak signal | None on record | — | — | — | — |
Solasia Pharma K.K.4597 · TSE | 1 asset: 1 Ph 2 | DarinaparsinPhase 2 · Peripheral T-Cell LymphomaWeak signal | None on record | — | — | — | — |
SPIMACOPrivate | 1 asset: 1 approved | Approved assets only | May 2027Lovotibeglogene autotemcel (Lyfgenia) · Phase 3 | — | — | — | — |
STCube, Inc.052020 · KOSDAQ | 1 asset: 1 Ph 2 | NelmastobartPhase 2 · Non-Small Cell Lung Cancer | 31 Aug 2027Nelmastobart · Phase 2 | — | — | — | — |
Sumitomo Pharma4506 · TSE | 7 assets: 3 approved, 1 Ph 3, 3 Ph 2 | VildagliptinPhase 3 · Type 2 DiabetesPartial signal | 30 Jun 2027Enzomenib · Phase 1/2 | — | — | — | $289M |
Summit TherapeuticsSMMT · Nasdaq | 1 asset: 1 Ph 3 | IvonescimabPhase 3 · Non-Small Cell Lung CancerReliable signal | Dec 2026Ivonescimab · Phase 3 | — | $630MSep 2026 | ~4.8 qtrs | $80M |
Sun Pharma Advanced Research Company LimitedSPARC · NSE | 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — |
Sun Pharmaceutical IndustriesSUNPHARMA · NSE | 6 assets: 4 approved, 1 Ph 3, 1 Ph 2 | LerodalcibepPhase 3 · Atherosclerotic Cardiovascular DiseaseReliable signal | Apr 2027Utreglutide · Phase 2 | — | $1.0BMar 2026 | Profitable | $401M |
Sunho Biologics2898 · HKEX | 2 assets: 1 Ph 2, 1 Ph 1 | IAP0971Phase 1/2 · Non-Small Cell Lung Cancer | 28 Feb 2027ISH0688 · Phase 1 | — | $24MJun 2025 | Ended Aug 2026 | — |
Sunshine Guojian Pharmaceutical688336 · SSE STAR Market | 3 assets: 2 Ph 3, 1 Ph 2 | Amdokitug (Yisaituo)Phase 3 · Psoriasis | 14 Jan 2027Amdokitug (Yisaituo) · Phase 3 | — | $243MDec 2025 | Profitable | — |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov). Cash shows its balance-sheet month; runway shows a month only when it comes from an earlier report.